Alopecia Areata (Investigational Adjunct)

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?

Not FDA-cleared for alopecia areata. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for alopecia areata is investigational.

¿Qué evidencia existe?

Tier C (investigational). Only anecdotal case reports; no randomized trials. Evidence-based therapy per AAD includes intralesional triamcinolone for limited patches (first line), topical immunotherapy with diphenylcyclopropenone (DPCP) for extensive disease, oral JAK inhibitors baricitinib (FDA-approved 2022) and ritlecitinib (FDA-approved 2023) for severe disease, topical and oral minoxidil as adjuncts, and topical / systemic corticosteroids. JAK inhibitors directly target the interferon-gamma / CD8+ T-cell pathway driving the disease.

Riesgos principales

• Bleeding from bite sites for 6 to 24 hours after detachment
• Bruising and tenderness over the scalp for 5 to 10 days
• Local skin infection or, rarely, Aeromonas infection
• Allergic reaction to leech saliva (uncommon)
• Triggering further hair loss at or near the bite sites in active disease
• Permanent visible scars at bite sites
• Delay or replacement of intralesional steroid or JAK inhibitor therapy with potential disease progression

Quién no debería considerar esto

• Patients with alopecia totalis or universalis (consider JAK inhibitors)
• Patients with active progressive AA in the last 3 months
• Patients on JAK inhibitor therapy (drug interaction unknown, theoretical bleeding risk)
• Patients with scalp psoriasis or seborrheic dermatitis at proposed sites
• Patients with diffuse hair loss not confirmed to be AA (needs workup)
• Patients on anticoagulants, with hemophilia, or with severe anemia

Qué preguntar a su clínico

• Has my diagnosis been confirmed (clinical exam, dermoscopy, or biopsy)?
• What is my SALT (Severity of Alopecia Tool) score, and what is the disease pattern?
• Have I tried intralesional triamcinolone for limited patches?
• Am I a candidate for a JAK inhibitor (baricitinib or ritlecitinib) for severe disease?
• What is the natural history of my AA, and has there been spontaneous regrowth?
• What is the realistic effect size with leech therapy versus proven options?
• What is the practitioner's experience and Aeromonas-prevention plan?

Cuándo buscar atención urgente

• Rapidly progressive hair loss across multiple body sites (suggests systemic autoimmune activity)
• Total or universal alopecia (consider urgent dermatology referral for JAK inhibitor)
• Spreading redness, warmth, pus, or red streaks (cellulitis)
• Bleeding from a bite site lasting more than 24 to 48 hours
• Fever above 38.0 C / 100.4 F or chills
• Eye redness, pain, or vision change (associated alopecia areata can have ocular involvement)
• Hives, throat tightness, or breathing difficulty